PE20121494A1 - Anticuerpos anti notch-1 - Google Patents

Anticuerpos anti notch-1

Info

Publication number
PE20121494A1
PE20121494A1 PE2011002114A PE2011002114A PE20121494A1 PE 20121494 A1 PE20121494 A1 PE 20121494A1 PE 2011002114 A PE2011002114 A PE 2011002114A PE 2011002114 A PE2011002114 A PE 2011002114A PE 20121494 A1 PE20121494 A1 PE 20121494A1
Authority
PE
Peru
Prior art keywords
seq
sequence
amino acids
variable region
variable
Prior art date
Application number
PE2011002114A
Other languages
English (en)
Spanish (es)
Inventor
Zdenek Hostomsky
Kang Li
John Andrew Lippincott
Qinghai Peng
Donna Marie Stone
Ping Wei
Original Assignee
Pfizer
Rinat Neuroscience Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42575817&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20121494(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer, Rinat Neuroscience Corp filed Critical Pfizer
Publication of PE20121494A1 publication Critical patent/PE20121494A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PE2011002114A 2009-06-18 2010-06-16 Anticuerpos anti notch-1 PE20121494A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21819309P 2009-06-18 2009-06-18

Publications (1)

Publication Number Publication Date
PE20121494A1 true PE20121494A1 (es) 2012-11-01

Family

ID=42575817

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011002114A PE20121494A1 (es) 2009-06-18 2010-06-16 Anticuerpos anti notch-1

Country Status (18)

Country Link
US (1) US9090690B2 (enExample)
EP (2) EP3431501A1 (enExample)
JP (2) JP6059985B2 (enExample)
KR (1) KR101570898B1 (enExample)
CN (1) CN102686610A (enExample)
AU (1) AU2010261364B2 (enExample)
BR (1) BRPI1011805A2 (enExample)
CA (1) CA2765989C (enExample)
CO (1) CO6480924A2 (enExample)
IL (1) IL217066A0 (enExample)
MX (1) MX337468B (enExample)
NZ (1) NZ597611A (enExample)
PE (1) PE20121494A1 (enExample)
PH (1) PH12011502609B1 (enExample)
RU (1) RU2011151287A (enExample)
SG (1) SG176731A1 (enExample)
WO (1) WO2010146550A1 (enExample)
ZA (1) ZA201109282B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009298569A1 (en) * 2008-10-01 2010-04-08 Genentech, Inc. Anti-Notch2 antibodies and methods of use
PE20121494A1 (es) * 2009-06-18 2012-11-01 Pfizer Anticuerpos anti notch-1
CA2775880A1 (en) * 2009-09-30 2011-04-07 Genentech, Inc. Anti-notch3 antagonist antibodies to treat gamma secretase inhibitor responsive and anti-notch1 antagonist antibody unresponsive t-cell leukemias
MX346995B (es) 2010-12-15 2017-04-06 Wyeth Llc Anticuerpos anti-notch1.
WO2012080891A1 (en) * 2010-12-15 2012-06-21 Rinat Neuroscience Corp. Anti-notch-1 antibodies
KR20150082548A (ko) 2012-11-07 2015-07-15 화이자 인코포레이티드 항-notch3 항체 및 항체-약물 접합체
CA2941733A1 (en) * 2014-03-07 2015-09-11 Oncomed Pharmaceuticals, Inc. Methods for treating cancer with notch1 antibodies
BR112017000130A2 (pt) 2014-07-11 2018-01-09 Genentech Inc método para atenuar a toxicidade associada à inibição da via de notch e método de tratamento do câncer
US11026996B2 (en) * 2016-05-25 2021-06-08 The Trustees Of Columbia University In The City Of New York Human Notch1 based fusion proteins as decoy inhibitors of jagged-notch signaling and DLL-notch signaling
JP2019535250A (ja) * 2016-10-29 2019-12-12 ジェネンテック， インコーポレイテッド 抗ｍｉｃ抗体及び使用方法
JP7525160B2 (ja) 2018-08-31 2024-07-30 Ｂｌｏｏｍ Ｔｅｃｈｎｏｌｏｇｙ 株式会社 終末糖化産物に対する抗体およびその使用
EP4585226A1 (en) 2022-09-09 2025-07-16 Institute Of Science Tokyo Therapeutic agent for coronavirus infection
CN121319198A (zh) * 2025-04-14 2026-01-13 北京光辉天成生物科技有限公司 一种高亲和力padi2抗体及其制备方法

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
GB8421551D0 (en) 1984-08-24 1984-09-26 Ici Plc Water-soluble dye
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
JP2989002B2 (ja) 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5278299A (en) 1991-03-18 1994-01-11 Scripps Clinic And Research Foundation Method and composition for synthesizing sialylated glycosyl compounds
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
ATE181571T1 (de) 1991-09-23 1999-07-15 Medical Res Council Methoden zur herstellung humanisierter antikörper
AU3144193A (en) 1991-11-21 1993-06-15 Board Of Trustees Of The Leland Stanford Junior University Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1993022332A2 (en) 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5786158A (en) 1992-04-30 1998-07-28 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
JP2698529B2 (ja) 1993-04-06 1998-01-19 浜松ホトニクス株式会社 イメージインテンシファイア装置
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
AU768269B2 (en) 1998-10-02 2003-12-04 Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The Apoptosis inducing agents and methods
US20030035798A1 (en) 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
KR101077001B1 (ko) 1999-01-15 2011-10-26 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
WO2002059285A1 (en) * 2000-10-27 2002-08-01 Fred Hutchinson Cancer Research Center Methods for immortalizing cells
US20030157108A1 (en) 2001-10-25 2003-08-21 Genentech, Inc. Glycoprotein compositions
US20030148954A1 (en) * 2001-11-02 2003-08-07 Wisconsin Alumni Research Foundation Agents and methods for modulating activator protein-1-mediated cellular processes
AU2002339157A1 (en) 2001-11-14 2003-05-26 Lorantis Limited Inhibitors of the notch signalling pathway for use in the treatment of cancer
CN102911987B (zh) 2002-04-09 2015-09-30 协和发酵麒麟株式会社 基因组被修饰的细胞
JP4558485B2 (ja) 2002-07-18 2010-10-06 正康 大河内 Ｎｏｔｃｈ由来新規ポリペプチドおよびそれを用いたバイオマーカー並びに試薬
CN102746399B (zh) 2002-12-24 2016-03-02 里纳特神经系统学公司 抗ngf抗体及其使用方法
AU2004294563B2 (en) 2003-11-26 2009-03-26 Health Research, Inc. Use of notch pathway interfering agents for treatment of plasma cell disorders
US20080220416A1 (en) 2004-05-20 2008-09-11 The Board Of Trustees Of The University Of Illinoi Compositions for Inhibiting Cell Growth and Inducing Apoptosis in Cancer Cells and Methods of Use Thereof
US20070077245A1 (en) 2004-08-04 2007-04-05 The Brigham And Women's Hospital, Inc. NOTCH mutations leading to increased receptor signaling
WO2006053063A2 (en) 2004-11-05 2006-05-18 The Regents Of The University Of California Notch-1 assay to detect neurodegenerative diseases
WO2006068953A2 (en) 2004-12-21 2006-06-29 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
US20080206753A1 (en) 2005-03-04 2008-08-28 The Hospital For Sick Children Methods for Cancer Prognosis
US7100777B1 (en) * 2005-07-07 2006-09-05 Jui-Chien Kao Hanger rack for hand tools
US20070072222A1 (en) 2005-09-23 2007-03-29 Franziska Boess FABP4 as biomarker for toxic effect
US20090305310A1 (en) 2005-11-22 2009-12-10 University Of Vermont And State Agricultural College Methods for Determining Notch Signaling and Uses Thereof
US20080241150A1 (en) 2006-05-15 2008-10-02 The Brigham And Women's Hospital, Inc. Functional negative regulatory domain sequences from human NOTCH1 and 2 and isolated LNR domains from human NOTCH1
PL2032166T3 (pl) 2006-06-13 2013-09-30 Oncomed Pharm Inc Kompozycje i sposoby diagnozowania i leczenia nowotworów
EP2134356A2 (en) 2007-03-05 2009-12-23 Board of Regents, The University of Texas System Negative genetic regulation of cancer cell renewal in synergy with notch- or numb-specific immunotherapy
PE20090321A1 (es) * 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
US8119366B2 (en) 2007-10-05 2012-02-21 Trojan Technologies, Ltd. Antennapedia-dominant negative mastermind-like construct
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP2307051B1 (en) 2008-07-08 2015-02-11 OncoMed Pharmaceuticals, Inc. Notch-binding agents and antagonists and methods of use thereof
WO2010059543A1 (en) 2008-11-20 2010-05-27 Merck Sharp & Dohme Corp. Generation and characterization of anti-notch antibodies for therapeutic and diagnostic use
PE20121494A1 (es) * 2009-06-18 2012-11-01 Pfizer Anticuerpos anti notch-1
CA2775880A1 (en) 2009-09-30 2011-04-07 Genentech, Inc. Anti-notch3 antagonist antibodies to treat gamma secretase inhibitor responsive and anti-notch1 antagonist antibody unresponsive t-cell leukemias
WO2011088215A2 (en) 2010-01-13 2011-07-21 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
WO2012080891A1 (en) 2010-12-15 2012-06-21 Rinat Neuroscience Corp. Anti-notch-1 antibodies
MX346995B (es) 2010-12-15 2017-04-06 Wyeth Llc Anticuerpos anti-notch1.

Also Published As

Publication number Publication date
CN102686610A (zh) 2012-09-19
KR101570898B1 (ko) 2015-11-23
IL217066A0 (en) 2012-02-29
MX2011013717A (es) 2012-05-29
US20120093813A1 (en) 2012-04-19
AU2010261364B2 (en) 2015-05-07
PH12011502609B1 (en) 2018-11-07
MX337468B (es) 2016-03-02
BRPI1011805A2 (pt) 2016-10-11
CO6480924A2 (es) 2012-07-16
WO2010146550A1 (en) 2010-12-23
AU2010261364A1 (en) 2012-01-19
EP3431501A1 (en) 2019-01-23
CA2765989C (en) 2016-11-29
PH12011502609A1 (en) 2012-11-12
RU2011151287A (ru) 2013-07-27
NZ597611A (en) 2014-03-28
JP6059985B2 (ja) 2017-01-11
KR20120071379A (ko) 2012-07-02
CA2765989A1 (en) 2010-12-23
EP2443151A1 (en) 2012-04-25
SG176731A1 (en) 2012-01-30
US9090690B2 (en) 2015-07-28
JP2016121162A (ja) 2016-07-07
JP2012530487A (ja) 2012-12-06
ZA201109282B (en) 2012-08-29

Similar Documents

Publication Publication Date Title
PE20121494A1 (es) Anticuerpos anti notch-1
PE20141398A1 (es) Anticuerpos neutralizantes de citomegalovirus humano
PE20131209A1 (es) Anticuerpos anti-fap
PE20200294A1 (es) Anticuerpos que se unen especificamente a pd-1 y metodos de uso
ES2670621T3 (es) Anticuerpos que se unen a OX40 y sus usos
PE20121649A1 (es) Anticuerpos monoclonales frente a progastrina y sus usos
PE20241623A1 (es) Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos
PE20140247A1 (es) Anticuerpos anti-cd38
PE20121691A1 (es) Formulacion de anticuerpos y regimenes terapeuticos
PE20120562A1 (es) Anticuerpo anti-axl
PE20130479A1 (es) Anticuerpos reactivos con b7-h3, fragmentos inmulogicamente activos de los mismos y usos de los mismos
PE20131403A1 (es) Anticuerpos anti-ox40 y metodos de uso de los mismos
PE20120340A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y melfalan
PE20141908A1 (es) Anticuerpos cd47 y metodos de uso los mismos
PE20130159A1 (es) Anticuerpos anti-cd40
PE20181805A1 (es) Composiciones y anticuerpos anti-tim-3
CO6430469A2 (es) Anticuerpos humanizados que se unen a cd19 y sus usos
AR085600A1 (es) Agentes de union biespecifica
MX342591B (es) Anticuerpos anti-pd-l1 y su uso para mejorar la función de células t.
PE20170912A1 (es) Conjugados de anticuerpo-farmaco
PE20141151A1 (es) Proteinas de union al antigeno cd27l
PE20141188A1 (es) Polipeptidos anticuerpos que antagonizan cd40
PE20110774A1 (es) Anticuerpos para ccr2
PE20140814A1 (es) Anticuerpos contra la angiopoyetina 2 humana
PE20120079A1 (es) Moleculas de anticuerpos mejoradas

Legal Events

Date Code Title Description
FC Refusal